Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Prescribers of Januvia (sitagliptin phosphate) (?)

Council Members in this Study Group: 40

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Harold Bays, MD, FACP, President and Medical Director, L-MARC Research CenterHarold Bays, MD, FACP
President and Medical Director
L-MARC Research Center

Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...

Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern HealthcareJoseph Bass, MD, PhD
Division Head of Endocrinology and Metabolism
Evanston Northwestern Healthcare

Joseph Bass, MD, PhD, is Assistant Professor of Medicine and Neurobiology at Northwestern University in Illinois and Division Head of Endocrinology and Metabolism at Evanston Northwestern Healthcare. He is also the Director of a federally-funded basic research program on obesity, diabetes, and lipid...

Dean Traiger, MD, Physician, Physicians’ Primary Care of Southwest Florida,P.L.Dean Traiger, MD
Physician
Physicians’ Primary Care of Southwest Florida,P.L.

Dean Traiger, MD, is the Owner of Physician's Primary Care of Southwest Florida. Dr. Traiger is board certified in Family Practice and specializes in general primary care across the continuum of pediatrics, adolescent, and adult and geriatric care. He is also focused on diabetes care, hypertension,...

Farhad Zangeneh, MD, Assistant Clinical Professor of Medicine , THE GEORGE WASHINGTON UNIVERSITY - CCFarhad Zangeneh, MD
Assistant Clinical Professor of Medicine
THE GEORGE WASHINGTON UNIVERSITY - CC

Farhad Zangeneh, MD, is an Assistant Clinical Professor of Medicine at George Washington University School of Medicine in District of Columbia. He is on the board of directors of ACCE and recently contributed to the AACE Diabetes guidelines. He is the Medical Director of Endocrine, Diabetes and Osteoporosis...

Michael Dempsey, Medical Director, Johns Hopkins Diabetes Center at Suburban HospitalMichael Dempsey
Medical Director
Johns Hopkins Diabetes Center at Suburban Hospital

Michael Dempsey, MD, is a Private Practitioner in Rockville, Maryland. He is the Medical Director of the Johns Hopkins Diabetes Center at Suburban Hospital, where he is also the Medical Director of Diabetes Education and Endocrine Subsection Chair. He is the Vice-President of the Mid-Atlantic chapter...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point.  Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...

Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com

 Should bisphosphonates be stopped in patients who have been taking them for many years?  Should they be used at all?

As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...

This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome. 

The recent findings regarding pioglitazone in a large, randomized, intravascular cardiac ultrasound study finally begin to show some indication of the expected efficacy for which many physicians chose to use the drug, i.e., to decrease cardiovascular disease or its progression.  From...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Contract Research Organization, Independent/Small

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Physician - Division Head
  • President
  • Medical Director
  • Director

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880